BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and Future Therapeutic Strategies. Front Immunol 2019;10:1418. [PMID: 31293582 DOI: 10.3389/fimmu.2019.01418] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Solimani F, Meier K, Ghoreschi K. Emerging Topical and Systemic JAK Inhibitors in Dermatology. Front Immunol 2019;10:2847. [PMID: 31849996 DOI: 10.3389/fimmu.2019.02847] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
2 Zeng FAP, Murrell DF. State-of-the-art review of human autoimmune blistering diseases (AIBD). Vet Dermatol 2021. [PMID: 34351020 DOI: 10.1111/vde.13008] [Reference Citation Analysis]
3 Kanokrungsee S, Anuntrangsee T, Tankunakorn J, Srisuwanwattana P, Suchonwanit P, Chanprapaph K. Rituximab Therapy for Treatment of Pemphigus in Southeast Asians. Drug Des Devel Ther 2021;15:1677-90. [PMID: 33911853 DOI: 10.2147/DDDT.S306046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Didona D, DI Zenzo G, Joly P. Paraneoplastic autoimmune multiorgan syndrome. Ital J Dermatol Venerol 2021;156:174-83. [PMID: 33070576 DOI: 10.23736/S2784-8671.20.06675-4] [Reference Citation Analysis]
5 Klufas DM, Amerson E, Twu O, Clark L, Shinkai K. Refractory pemphigus vulgaris successfully treated with ofatumumab. JAAD Case Rep 2020;6:734-6. [PMID: 32715065 DOI: 10.1016/j.jdcr.2020.05.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Mahmoudi H, Tavakolpour S, Balighi K, Farid AS, Nili A, Jan D, Daneshpazhooh M. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. Dermatol Ther 2021;34:e14633. [PMID: 33280226 DOI: 10.1111/dth.14633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wang HX, Yang Y, Hu JY, Zhang LM, Cai YF, Guo H, Xiao T, Chen HD, Gao XH, Qiao S. Serum Detection of Anti-thyroid Peroxidase and Anti-thyroglobulin Antibodies in Chinese Patients With Pemphigus Vulgaris and Pemphigus Foliaceus and Literature Review. Front Immunol 2021;12:653356. [PMID: 33796116 DOI: 10.3389/fimmu.2021.653356] [Reference Citation Analysis]
8 Eming R, Zimmer CL, Hertl M. Pemphigus: a critical analysis on clinical subtypes, pathogenesis, diagnostics and established novel therapeutics. Ital J Dermatol Venerol 2021;156:121-3. [PMID: 33314892 DOI: 10.23736/S2784-8671.20.06790-5] [Reference Citation Analysis]
9 Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, Roussaki-Schulze AV, Sinclair R, Bassukas ID, Thomas D, Neale A, Arora P, Caux F, Werth VP, Gourlay SG, Joly P; BELIEVE trial investigators. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. Br J Dermatol 2021. [PMID: 33942286 DOI: 10.1111/bjd.20431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Frampton JE. Rituximab: A Review in Pemphigus Vulgaris. Am J Clin Dermatol 2020;21:149-56. [PMID: 31838645 DOI: 10.1007/s40257-019-00497-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
11 Kridin K, Ahmed AR. The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review. Expert Opin Biol Ther 2021;21:443-54. [PMID: 33455475 DOI: 10.1080/14712598.2021.1874915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Solimani F, Meier K, Zimmer CL, Hashimoto T. Immune serological diagnosis of pemphigus. Ital J Dermatol Venerol 2021;156:151-60. [PMID: 33228340 DOI: 10.23736/S2784-8671.20.06788-7] [Reference Citation Analysis]
13 Pawar M, Singh M. Systemic steroids and risk of fecal-oral shedding and increased transmission of SARS-CoV-2 in pemphigus cases. Clin Dermatol 2020;38:750-6. [PMID: 33341209 DOI: 10.1016/j.clindermatol.2020.06.006] [Reference Citation Analysis]
14 Costan VV, Popa C, Hâncu MF, Porumb-Andrese E, Toader MP. Comprehensive review on the pathophysiology, clinical variants and management of pemphigus (Review). Exp Ther Med 2021;22:1335. [PMID: 34630689 DOI: 10.3892/etm.2021.10770] [Reference Citation Analysis]
15 Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M. COVID-19 and implications for dermatological and allergological diseases. J Dtsch Dermatol Ges 2020;18:815-24. [PMID: 32717116 DOI: 10.1111/ddg.14195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
16 Bilgic A, Murrell DF. What is novel in the clinical management of pemphigus. Expert Review of Clinical Pharmacology 2019;12:973-80. [DOI: 10.1080/17512433.2019.1670059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
17 Bardazzi F, Loi C, Chessa Marco A, Di Altobrando A, Filippi F, Lacava R, Viviani F, Balestri R, Leuzzi M, Sacchelli L. Therapeutic approaches and targets for treatment of autoimmune bullous diseases. Dermatol Ther 2021;:e15032. [PMID: 34145701 DOI: 10.1111/dth.15032] [Reference Citation Analysis]
18 Aidi S, Daneshpazhooh M, Eslami M, Azizpour A, Toosi R, Mollazadeh R. Adverse electrocardiographic effects of rituximab infusion in pemphigus patients. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.14299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Yamagami J, Ujiie H, Aoyama Y, Ishii N, Tateishi C, Ishiko A, Ichijima T, Hagihara S, Hashimoto K, Amagai M. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus. J Dermatol Sci 2021:S0923-1811(21)00148-1. [PMID: 34376340 DOI: 10.1016/j.jdermsci.2021.07.002] [Reference Citation Analysis]
20 Marinović B, Miše J, Jukić IL, Bukvić Mokos Z. Pemphigus-The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic. Biomedicines 2021;9:1555. [PMID: 34829784 DOI: 10.3390/biomedicines9111555] [Reference Citation Analysis]
21 Sliwiak P, Folwarczny E, Didona D, Fink S, Wiegand C, Hanschmann EM, Hertl M, Hudemann C. Redox Enzymes of the Thioredoxin Family as Potential and Novel Markers in Pemphigus. Oxid Med Cell Longev 2021;2021:6672693. [PMID: 33868574 DOI: 10.1155/2021/6672693] [Reference Citation Analysis]
22 Ronchetti S, Ayroldi E, Ricci E, Gentili M, Migliorati G, Riccardi C. A Glance at the Use of Glucocorticoids in Rare Inflammatory and Autoimmune Diseases: Still an Indispensable Pharmacological Tool? Front Immunol 2020;11:613435. [PMID: 33584696 DOI: 10.3389/fimmu.2020.613435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 R H, Ramani P, Tilakaratne WM, Sukumaran G, Ramasubramanian A, Krishnan RP. Critical appraisal of different triggering pathways for the pathobiology of pemphigus vulgaris-A review. Oral Dis 2021. [PMID: 34152662 DOI: 10.1111/odi.13937] [Reference Citation Analysis]
24 Bishnoi A, De D, Handa S, Mahajan R. Biologics in autoimmune bullous diseases: Current scenario. Indian J Dermatol Venereol Leprol 2021;87:611-20. [PMID: 34245525 DOI: 10.25259/IJDVL_886_19] [Reference Citation Analysis]
25 Didona D, Hertl M. [Paraneoplastic autoimmune dermatoses]. Hautarzt 2021;72:277-87. [PMID: 33646324 DOI: 10.1007/s00105-021-04773-w] [Reference Citation Analysis]
26 Mangkorntongsakul V, Phan K, Smith SD. Pemphigus and rheumatoid arthritis: A systematic review and meta-analysis. Dermatol Ther 2021;34:e14845. [PMID: 33528863 DOI: 10.1111/dth.14845] [Reference Citation Analysis]
27 Zhao W, Wang J, Zhu H, Pan M. Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies. Clin Rev Allergy Immunol 2021. [PMID: 34350539 DOI: 10.1007/s12016-021-08882-1] [Reference Citation Analysis]
28 Maity S, Banerjee I, Sinha R, Jha H, Ghosh P, Mustafi S. Nikolsky's sign: A pathognomic boon. J Family Med Prim Care 2020;9:526-30. [PMID: 32318376 DOI: 10.4103/jfmpc.jfmpc_889_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Hudemann C, Maglie R, Llamazares M, Beckert B, Didona D, Tikkanen R, Schmitt T, Hashimoto T, Waschke J, Hertl M, Eming R. Human desmocollin 3-specific IgG antibodies are pathogenic in a humanized HLA-class II transgenic mouse model of pemphigus. J Invest Dermatol 2021:S0022-202X(21)01440-8. [PMID: 34265330 DOI: 10.1016/j.jid.2021.06.017] [Reference Citation Analysis]
30 Juratli HA, Avci P, Horváth B. Clinicians' pearls and myths in pemphigus. Ital J Dermatol Venerol 2021;156:142-6. [PMID: 33960749 DOI: 10.23736/S2784-8671.21.06810-3] [Reference Citation Analysis]
31 Kubanov AA, Deryabin DG, Shpilevaya MV, Karamova AE, Nikonorov AA, Larina EN, Aliev TK, Dolgikh DA, Bobik TV, Smirnov IV, Gabibov AG, Kirpichnikov MP. Analysis of the Specificity of Auto-Reactive Antibodies to Individual Fragments of the Extracellular Domain of Desmoglein 3 in Patients with Pemphigus Vulgaris. Bull Exp Biol Med 2021;171:475-9. [PMID: 34542752 DOI: 10.1007/s10517-021-05254-9] [Reference Citation Analysis]
32 Didona D, Fania L, Di Zenzo G, Didona B. Erythromycin-induced pemphigus foliaceus successfully treated with etanercept. Dermatol Ther 2020;33:e14201. [PMID: 32808715 DOI: 10.1111/dth.14201] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Maglie R, Genovese G, Solimani F, Guglielmo A, Pileri A, Portelli F, Hertl M, Marzano AV, Antiga E. Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review. Am J Clin Dermatol 2020;21:833-54. [PMID: 32813229 DOI: 10.1007/s40257-020-00553-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
34 Mohebi F, Tavakolpour S, Teimourpour A, Toosi R, Mahmoudi H, Balighi K, Ghandi N, Ghiasi M, Nourmohammadpour P, Lajevardi V, Abedini R, Azizpour A, Nasimi M, Daneshpazhooh M. Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies. BMC Dermatol 2020;20:13. [PMID: 33129291 DOI: 10.1186/s12895-020-00105-y] [Reference Citation Analysis]
35 Meier K, Holstein J, Solimani F, Waschke J, Ghoreschi K. Case Report: Apremilast for Therapy-Resistant Pemphigus Vulgaris. Front Immunol 2020;11:588315. [PMID: 33193415 DOI: 10.3389/fimmu.2020.588315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
36 Fetter T, Niebel D, Braegelmann C, Wenzel J. Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases-Implications for Therapeutic Approaches. Cells 2020;9:E2627. [PMID: 33297481 DOI: 10.3390/cells9122627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Giannetti L, Murri Dello Diago A. Therapy of autoimmune mouth bullous disease: 2020 review. Dermatol Ther 2021;34:e14376. [PMID: 33029891 DOI: 10.1111/dth.14376] [Reference Citation Analysis]
38 Mazloom E, Daneshpazhooh M, Shokouhi Shoormasti R, Balighi K, Mahmoudi H, Moradi Ketisari M, Eslami Faresani V, Ghandi N. Intralesional injection of biosimilar rituximab in recalcitrant mucocutaneous lesions of patients with pemphigus vulgaris: A pilot study. Dermatol Ther 2020;33:e14407. [PMID: 33051954 DOI: 10.1111/dth.14407] [Reference Citation Analysis]
39 Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M. COVID‐19 und Auswirkungen auf dermatologische und allergologische Erkrankungen. J Dtsch Dermatol Ges 2020;18:815-25. [PMID: 32881343 DOI: 10.1111/ddg.14195_g] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Konop M, Rybka M, Drapała A. Keratin Biomaterials in Skin Wound Healing, an Old Player in Modern Medicine: A Mini Review. Pharmaceutics 2021;13:2029. [PMID: 34959311 DOI: 10.3390/pharmaceutics13122029] [Reference Citation Analysis]
41 Wu PY, Li TM, Chen SI, Chen CJ, Chiou JS, Lin MK, Tsai FJ, Wu YC, Lin TH, Liao CC, Huang SM, Lin YN, Liang WM, Lin YJ. Complementary Chinese Herbal Medicine Therapy Improves Survival in Patients With Pemphigus: A Retrospective Study From a Taiwan-Based Registry. Front Pharmacol 2020;11:594486. [PMID: 33362549 DOI: 10.3389/fphar.2020.594486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Russo I, Miotto S, Saponeri A, Alaibac M. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study. Expert Opin Biol Ther 2020;20:673-8. [PMID: 32027810 DOI: 10.1080/14712598.2020.1727440] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
43 Liu Y, Zhang B, Ma J, Wang H, Fan X, Zheng K, Chen L, Li X, Qin Y, Li L, Li X. Double-filtration plasmapheresis combined with immunosuppressive treatment for severe pemphigus: 10 years' experience of a single center in China. J Clin Apher 2021;36:20-7. [PMID: 32812668 DOI: 10.1002/jca.21829] [Reference Citation Analysis]
44 Maglie R, Antiga E, Payne AS. B-cell targeted therapies in pemphigus. Ital J Dermatol Venerol 2021;156:161-73. [PMID: 33016669 DOI: 10.23736/S2784-8671.20.06694-8] [Reference Citation Analysis]
45 Patil S, Gs V, Sarode GS, Sarode SC, Khurayzi TA, Mohamed Beshir SE, Gadbail AR, Gondivkar S. Exploring the role of immunotherapeutic drugs in autoimmune diseases: A comprehensive review. J Oral Biol Craniofac Res 2021;11:291-6. [PMID: 33948430 DOI: 10.1016/j.jobcr.2021.02.009] [Reference Citation Analysis]
46 Lin X, Lu L. B Cell-Mediated Autoimmune Diseases. Adv Exp Med Biol 2020;1254:145-60. [PMID: 32323275 DOI: 10.1007/978-981-15-3532-1_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Holstein J, Solimani F, Baum C, Meier K, Pollmann R, Didona D, Tekath T, Dugas M, Casadei N, Hudemann C, Polakova A, Matthes J, Schäfer I, Yazdi AS, Eming R, Hertl M, Pfützner W, Ghoreschi K, Möbs C. Immunophenotyping in pemphigus reveals a TH17/TFH17 cell-dominated immune response promoting desmoglein1/3-specific autoantibody production. J Allergy Clin Immunol 2021;147:2358-69. [PMID: 33221382 DOI: 10.1016/j.jaci.2020.11.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
48 Saito R, Tanaka A, Takahagi S, Tanaka M, Hide M. Pemphigus foliaceus with inconsistent findings between clinical features and titres of antidesmoglein autoantibodies. Australas J Dermatol 2021;62:e148-9. [PMID: 32862438 DOI: 10.1111/ajd.13453] [Reference Citation Analysis]
49 Di Lernia V, Casanova DM, Goldust M, Ricci C. Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment. Dermatol Pract Concept 2020;10:e2020050. [PMID: 32642305 DOI: 10.5826/dpc.1003a50] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
50 Shahrigharahkoshan S, Dadkhahfar S, Mozafari N, Shahidi-Dadras M. A review of reported infectious events following rituximab therapy in pemphigus patients. Dermatol Ther 2021;:e15264. [PMID: 34907628 DOI: 10.1111/dth.15264] [Reference Citation Analysis]
51 Simpson K, Low ZM, Yap T, Kern JS, Scardamaglia L. Ultralow-dose rituximab in pemphigus: a single-centre experience. Br J Dermatol 2021. [PMID: 34652809 DOI: 10.1111/bjd.20819] [Reference Citation Analysis]
52 Tham HL, Linder KE, Olivry T. Deep pemphigus (pemphigus vulgaris, pemphigus vegetans and paraneoplastic pemphigus) in dogs, cats and horses: a comprehensive review. BMC Vet Res 2020;16:457. [PMID: 33228633 DOI: 10.1186/s12917-020-02677-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Bağcı IS, Aoki R, Vladimirova G, Sárdy M, Ruzicka T, French LE, Hartmann D. Simultaneous immunofluorescence and histology in pemphigus vulgaris using ex vivo confocal laser scanning microscopy. J Biophotonics 2021;14:e202000509. [PMID: 33491324 DOI: 10.1002/jbio.202000509] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 McDonald C, Xanthopoulos C, Kostareli E. The role of Bruton's tyrosine kinase in the immune system and disease. Immunology 2021;164:722-36. [PMID: 34534359 DOI: 10.1111/imm.13416] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Sinagra JL, Vedovelli C, Binazzi R, Salemme A, Moro F, Mazzanti C, Didona B, Di Zenzo G. Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab. Front Immunol 2021;12:665522. [PMID: 33936104 DOI: 10.3389/fimmu.2021.665522] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Benesh G, Andriano TM, Cohen SR. Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy. JAAD Case Rep 2021;16:12-5. [PMID: 34504927 DOI: 10.1016/j.jdcr.2021.08.005] [Reference Citation Analysis]
57 Domínguez-Franco A, Méndez-Flores S, Ramírez-Marín HA, Olvera-Rodriguez V, Domínguez-Cherit JG. Pain Management in Patients with Severe Pemphigus Vulgaris. J Pain Palliat Care Pharmacother 2021;:1-5. [PMID: 34519607 DOI: 10.1080/15360288.2021.1963906] [Reference Citation Analysis]
58 Scarsella L, Pollmann R, Amber KT. Autoreactive T cells in pemphigus: perpetrator and target. Ital J Dermatol Venerol 2021;156:124-33. [PMID: 33179878 DOI: 10.23736/S2784-8671.20.06706-1] [Reference Citation Analysis]
59 Viti G, Forcella C, Feliciani C, Murrell DF. Beyond the skin: disease parameters in pemphigus. Ital J Dermatol Venerol 2021;156:147-50. [PMID: 33960750 DOI: 10.23736/S2784-8671.21.06678-5] [Reference Citation Analysis]
60 Frew JW, Grand D, Navrazhina K, Krueger JG. Beyond antibodies: B cells in Hidradenitis Suppurativa: Bystanders, contributors or therapeutic targets? Exp Dermatol 2020;29:509-15. [PMID: 32145106 DOI: 10.1111/exd.14092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
61 Beheshti SA, Shamsasenjan K, Ahmadi M, Abbasi B. CAR Treg: A new approach in the treatment of autoimmune diseases. Int Immunopharmacol 2022;102:108409. [PMID: 34863655 DOI: 10.1016/j.intimp.2021.108409] [Reference Citation Analysis]